Several studies have highlighted the potential benefits of omega-3 polyunsaturated fatty acids (n-3 PUFAs), namely eicosapentaenoic (EPA) and docosahexaenoic acid (DHA) in treating cholestatic diseases such as PBC and PSC: 1) n-3 PUFAs protect hepatocytes against BA toxicity [24–27]; 2) n-3 PUFAs protect against PBC/PSC symptoms and complications such as necro-inflammatory liver injury [28], hepatic fibrosis [29], and hepatocellular carcinoma [30]; and 3) n-3 PUFAs regulate BA-related genes, such as CYP7A1 [24,31] and NTCP [32]. Here, SLC10A1 is linked to primary biliary cholangitis.